Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma: subgroup analyses from CheckMate 040

被引：0

作者：

Sangro, Bruno ^{[1
,2
]}

He, Aiwu Ruth ^{[3
]}

Yau, Thomas ^{[4
]}

Hsu, Chiun ^{[5
]}

Kang, Yoon-Koo ^{[6
,7
]}

Kim, Tae-You ^{[8
]}

Santoro, Armando ^{[9
]}

Melero, Ignacio ^{[10
]}

Kudo, Masatoshi ^{[11
]}

Ho, Ming-Mo ^{[12
]}

Matilla, Ana ^{[13
,14
]}

Tovoli, Francesco ^{[15
]}

Knox, Jennifer ^{[16
]}

El-Rayes, Bassel ^{[17
]}

Acosta, Mirelis Rivera ^{[18
]}

Neely, Jaclyn ^{[19
]}

Shen, Yun ^{[19
]}

Tschaika, Marina ^{[19
]}

El-Khoureiry, Anthony ^{[20
]}

机构：

[1] Clin Univ Navarra, Pamplona, Spain

[2] CIBEREHD, Pamplona, Spain

[3] Georgetown Univ Hosp, Washington, DC 20007 USA

[4] Univ Hong Kong, Hong Kong, Peoples R China

[5] Natl Taiwan Univ Hosp, Taipei, Taiwan

[6] Asan Med Ctr, Seoul, South Korea

[7] Univ Ulsan, Seoul, South Korea

[8] Seoul Natl Univ, Seoul, South Korea

[9] Ist Clin Humanitas, Rozzano, Italy

[10] Univ Navarra, Pamplona, Spain

[11] Kindai Univ, Fac Med, Osaka, Japan

[12] Chang Gung Mem Hosp, Taipei, Taiwan

[13] Hosp Gen Univ Gregorio Maranon, Serv Digest, Madrid, Spain

[14] CIBEREHD, Madrid, Spain

[15] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy

[16] Princess Margaret Canc Ctr, Toronto, ON, Canada

[17] Emory Univ, Winship Ctr, Atlanta, GA 30322 USA

[18] Fdn Invest, San Juan, PR USA

[19] Bristol Myers Squibb, Princeton, NJ USA

[20] USC, Norris Comprehens Canc Ctr, Los Angeles, CA USA

来源：

JOURNAL OF HEPATOLOGY | 2020年 / 73卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

LBO11

引用

页码：S121 / S122

页数：2

共 50 条

[31] Hepatic safety and biomarker assessments in sorafenib-experienced patients with advanced hepatocellular carcinoma treated with nivolumab in the CheckMate-040 study
Meyer, T.
Melero, I.
Yau, T.
Hsu, C.
Kudo, M.
Choo, S. -P.
Trojan, J.
Welling, T.
Kang, Y. -K.
Yeo, W.
Chopra, A.
Baakili, A.
Cruz, C. D.
Zhao, H.
Neely, J.
Crocenzi, T.
El-Khoureiry, A.
Sangro, B.
JOURNAL OF HEPATOLOGY, 2018, 68 : S16 - S16
[32] Safety and preliminary efficacy of nivolumab in patients with advanced hepatocellular carcinoma: interim analysis of the phase 1/2 CheckMate-040 study
Melero, I.
Sangro, B.
Yau, T.
Hsu, C.
Kudo, M.
Crocenzi, T.
Kim, T-Y.
Choo, S. P.
Trojan, J.
Meyer, T.
Welling, T. H., III
Yeo, W.
Chopra, A.
Anderson, J.
Dela Cruz, C.
Lang, L.
Neely, J.
El-Khoueiry, A.
ANNALS OF ONCOLOGY, 2016, 27
[33] Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)
Hodi, F. Stephen
Chapman, Paul B.
Sznol, Mario
Lao, Christopher D.
Gonzalez, Rene
Smylie, Michael
Daniels, Gregory A.
Thompson, John A.
Kudchadkar, Ragini
Sharfman, William
Atkins, Michael
Spigel, David R.
Pavlick, Anna
Monzon, Jose
Kim, Kevin B.
Ernst, Scott
Khushalani, Nikhil, I
van Dijck, Wim
Lobo, Maurice
Hogg, David
MELANOMA RESEARCH, 2021, 31 (01) : 67 - 75
[34] Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma (HCC): Survival, Hepatic Safety, and Biomarker Assessments in CheckMate 040
Sangro, Bruno
Melero, Ignacio
Yau, Thomas
Hsu, Chiun
Kudo, Masatoshi
Kim, Tae-You
Choo, Su-Pin
Trojan, Jorg
Welling, Theodore H.
Meyer, Timothy
Kang, Yoon-Koo
Yeo, Winnie
Chopra, Akhil
Baakili, Adyb
dela Cruz, Christine
Zhao, Huanyu
Neely, Jaclyn
Crocenzi, Todd S.
El-Khoueiry, Anthony B.
HEPATOLOGY, 2017, 66 : 82A - 82A
[35] HEPATIC SAFETY AND BIOMARKER ASSESSMENTS IN SORAFENIB-EXPERIENCED PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA TREATED WITH NIVOLUMAB IN THE CHECKMATE-040 STUDY
Crocenzi, Todd
Meyer, Tim
Melero, Ignacio
Yau, Thomas
Hsu, Chiun
Kudo, Masatoshi
Choo, Su-Pin
Trojan, Jorg
Welling, Theodore
Kang, Yoon-Koo
Yeo, Winnie
Chopra, Akhil
Baakili, Adyb
dela Cruz, Christine
Zhao, Huanyu
Neely, Jaclyn
El-Khoueiry, Anthony
Sangro, Bruno
GASTROENTEROLOGY, 2018, 154 (06) : S1234 - S1234
[36] Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538
Klein, Oliver
Senko, Clare
Carlino, Matteo S.
Markman, Ben
Jackett, Louise
Gao, Bo
Lum, Caroline
Kee, Damien
Behren, Andreas
Palmer, Jodie
Cebon, Jonathan
ONCOIMMUNOLOGY, 2021, 10 (01):
[37] Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma (HCC): CheckMate 040 study.
Crocenzi, Todd S.
El-Khoueiry, Anthony B.
Yau, Thomas Cheung
Melero, Ignacio
Sangro, Bruno
Kudo, Masatoshi
Hsu, Chiun
Trojan, Jorg
Kim, Tae -You
Choo, Su -Pin
Meyer, Tim
Kang, Yoon-Koo
Yeo, Winnie
Chopra, Akhil
Baakili, Adyb
Dela Cruz, Christine Marie
Lang, Lixin
Neely, Jaclyn
Welling, Theodore
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[38] Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040
El-Khoueiry, A. B.
Trojan, J.
Meyer, T.
Yau, T.
Melero, I.
Kudo, M.
Hsu, C.
Kim, T. -y.
Choo, S. -p.
Kang, Y. -k.
Yeo, W.
Chopra, A.
Soleymani, S.
Yao, J.
Neely, J.
Tschaika, M.
Welling, T. H.
Sangro, B.
ANNALS OF ONCOLOGY, 2024, 35 (04) : 381 - 391
[39] Checkmate-040: Nivolumab (NIVO) in patients (pts) with advanced hepatocellular carcinoma (aHCC) and Child-Pugh B (CPB) status.
Kudo, Masatoshi
Matilla, Ana
Santoro, Armando
Melero, Ignacio
Gracian, Antonio Cubillo
Acosta-Rivera, Mirelis
Choo, Su Pin
El-Khoueiry, Anthony B.
Kuromatsu, Ryoko
El-Rayes, Bassel F.
Numata, Kazushi
Itoh, Yoshito
Di Costanzo, Francesco
Crysler, Oxana V.
Reig, Maria
Shen, Yun
Neely, Jaclyn
Dela Cruz, Christine Marie
Baccan, Carlos
Sangro, Bruno
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
[40] First-Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long-Term Outcomes from CheckMate 012
Gettinger, Scott
Rizvi, Naiyer
Chow, Laura
Borghaei, Hossein
Brahmer, Julie
Shepherd, Frances
Ready, Neal
Gerber, David
Antonia, Scott
Goldman, Jonathan W.
Juergens, Rosalyn
Geese, William
Young, Tina
L, Xuemei, I
Hellmann, Matthew
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S250 - S251

← 1 2 3 4 5 →